Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J. T. Wasicak"'
Autor:
J. Y. L. Chung, J. T. Wasicak
Publikováno v:
ChemInform. 22
Publikováno v:
ChemInform. 23
Autor:
D S, Garvey, J T, Wasicak, J Y, Chung, Y K, Shue, G M, Carrera, P D, May, M M, McKinney, D, Anderson, E, Cadman, L, Vella-Rountree
Publikováno v:
Journal of Medicinal Chemistry. 35:1550-1557
A series of novel 2-substituted acetylenic pyrrolidines and piperidines related to oxotremorine (1) were prepared and evaluated in vitro as muscarinic cholinergic agents at brain M1 and M2 receptors. One analogue, 3-(2-oxo-1-pyrrolidinyl)-1-[2(R)-pyr
Autor:
A W, Bannon, M W, Decker, P, Curzon, M J, Buckley, D J, Kim, R J, Radek, J K, Lynch, J T, Wasicak, N H, Lin, W H, Arnold, M W, Holladay, M, Williams, S P, Arneric
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 285(2)
The antinociceptive effects of ABT-594, a novel nicotinic acetylcholine receptor (nAChR) ligand, were examined in rats in models of acute thermal (hot box) and persistent chemical (formalin test) pain. Also, the effects of ABT-594 treatment on motor
Autor:
D L, Donnelly-Roberts, P S, Puttfarcken, T A, Kuntzweiler, C A, Briggs, D J, Anderson, J E, Campbell, M, Piattoni-Kaplan, D G, McKenna, J T, Wasicak, M W, Holladay, M, Williams, S P, Arneric
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 285(2)
The discovery of (+/-)-epibatidine, a naturally occurring neuronal nicotinic acetylcholine receptor (nAChR) agonist with antinociceptive activity 200-fold more potent than that of morphine, has renewed interest in the potential role of nAChRs in pain
Autor:
M W, Decker, J D, Brioni, J P, Sullivan, M J, Buckley, R J, Radek, J L, Raszkiewicz, C H, Kang, D J, Kim, W J, Giardina, J T, Wasicak
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 270(1)
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418), an isoxazole analog of (-)-nicotine, is a potent agonist at the alpha-4/beta-2 subtype of neuronal nicotinic acetylcholine receptor (nAChR) that exists in mammalian brain (Arneric et al., 1
Autor:
Scott F. Robinson, Yvonne C. Martin, Peter Curzon, D. J. B. Kim, S C Quigley, David S. Garvey, J. T. Wasicak, Kennan C. Marsh, M. J. Buckley, Stephen P. Arneric, Jerry J. Buccafusco, P. A. Pavlik, Mark W. Holladay, Alvin V. Terry, David J. Anderson, Susan Wonnacott, Michael W. Decker, Alyssa B. O'Neill, Jorge D. Brioni, Richard J. Radek, S. P. Amend, Michael Williams, A. D. Rodrigues, M. Majchrzak, G. Wilkie, K. C. Marsh, M. W. Decke, James R. Pauly, William J. Jackson, James P. Sullivan, Diana L. Donnelly-Roberts
Publikováno v:
Experientia Supplementum ISBN: 9783764350871
With the plethora of receptor targets evolving as the result of nicotinic acetylcholine receptor (nAChR) cloning it is possible that new molecular entities selective for subtypes of nAChRs can be developed which are potentially free of the side effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2ce4b2a6422d1b2c0bfafe30dd65b73
https://doi.org/10.1007/978-3-0348-7416-8_10
https://doi.org/10.1007/978-3-0348-7416-8_10